Researchers at the University of Pittsburgh School of Medicine in the US have reported encouraging results from initial tests of a Covid-19 vaccine candidate, PittCoVacc, delivered using a fingertip-sized patch in mice.
In the animals, the candidate was able to generate antibodies specific to SARS-CoV-2 at levels that might be enough to neutralise the virus, noted the researchers.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The findings have been detailed in eBioMedicine published by The Lancet journal.
